Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes
- PMID: 3583507
- DOI: 10.1016/0192-0561(87)90088-9
Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes
Abstract
The purpose of this study was to analyse on biochemical and functional levels the interaction of free and liposome-encapsulated nor-muramyl dipeptide (nor-MDP) or muramyl tripeptide phosphatidylethanolamine (MTP-PE) with human peripheral blood monocytes. The activation of tumoricidal properties in monocytes by free MTP-PE required approximately 40-fold less material than free nor-MDP. Encapsulation of either MTP-PE or nor-MDP within multilamellar liposomes (MLV) increased the efficiency of the immunomodulators for activation of monocytes. The initial interaction of free 3H-nor-MDP or 3H-MTP-PE with monocytes was influenced by lipophilic derivatization, but neither derivatives exhibited characteristics of specific binding to the monocyte surface. The encapsulation of 3H-nor-MDP or 3H-MTP-PE within MLV increased uptake of both compounds by monocytes. The metabolic fate of MLV-entrapped 3H-nor-MDP was unaltered, but liposome encapsulation retarded the metabolism of 3H-MTP-PE. Collectively, the data suggest that the activation of monocytes by muramyl peptides results from an intracellular interaction which can be modulated by both lipophilic derivatization and/or liposome-encapsulation of this immunomodulator.
Similar articles
-
Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.J Immunol. 1985 Aug;135(2):1372-7. J Immunol. 1985. PMID: 4008926
-
A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.Cancer Immunol Immunother. 1986;22(3):191-6. doi: 10.1007/BF00200032. Cancer Immunol Immunother. 1986. PMID: 3731204 Free PMC article.
-
Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.Cancer Res. 1986 Oct;46(10):5039-44. Cancer Res. 1986. PMID: 3489519
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Hematol Oncol Clin North Am. 1995. PMID: 7490249 Review.
-
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.Cancer Treat Res. 1993;62:101-7. doi: 10.1007/978-1-4615-3518-8_14. Cancer Treat Res. 1993. PMID: 8096724 Review.
Cited by
-
Mifamurtide for the treatment of nonmetastatic osteosarcoma.Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Expert Opin Pharmacother. 2011. PMID: 21226638 Free PMC article. Review.
-
Harnessing the Therapeutic Potential of Biomacromolecules through Intracellular Delivery of Nucleic Acids, Peptides, and Proteins.Adv Healthc Mater. 2022 Jun;11(12):e2102600. doi: 10.1002/adhm.202102600. Epub 2022 Mar 23. Adv Healthc Mater. 2022. PMID: 35285167 Free PMC article. Review.
-
pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling.J Biol Chem. 2009 Aug 28;284(35):23818-29. doi: 10.1074/jbc.M109.033670. Epub 2009 Jul 1. J Biol Chem. 2009. PMID: 19570976 Free PMC article.
-
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs.Pharmaceutics. 2019 Mar 7;11(3):110. doi: 10.3390/pharmaceutics11030110. Pharmaceutics. 2019. PMID: 30866479 Free PMC article. Review.
-
Managing sarcoma: where have we come from and where are we going?Ther Adv Med Oncol. 2017 Oct;9(10):637-659. doi: 10.1177/1758834017728927. Epub 2017 Sep 20. Ther Adv Med Oncol. 2017. PMID: 28974986 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources